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Oncostatin M-Induced and Constitutive Activation of the
JAK2/STAT5/CIS Pathway Suppresses CCL1, but Not CCL7
and CCL8, Chemokine Expression1
Christoph Hintzen,* Claude Haan,† Jan P. Tuckermann,‡ Peter C. Heinrich,§
and Heike M. Hermanns2*
The recruitment of leukocytes to injured tissue is crucial for the initiation of inflammatory responses as well as for immune
surveillance to fight tumor progression. In this study, we show that oncostatin M, a member of the IL-6-type cytokine family and
potent proinflammatory cytokine stimulates the expression of the chemokines CCL1, CCL7, and CCL8 in primary human dermal
fibroblasts at a faster kinetic than IL-1 or TNF-. The production of CCL1 and CCL8 is important for migration of monocytes,
while specific Abs against CCL1 additionally inhibit the migration of T lymphocytes. We identify the mitogen-activated protein
kinases ERK1/2 and p38 as crucial factors for the enhanced expression of CCL1 and CCL8. Depletion of the ERK1/2 target genes
c-Jun or c-Fos strongly decrease CCL1 and CCL8 expression, while p38 MAPK prolongs the half-life of CCL1, CCL7, and CCL8
mRNA through inhibition of tristetraprolin. None of the STAT transcription factors STAT1, STAT3, or STAT5 stimulate tran-
scription of CCL1 or CCL8. However, we identify a negative regulatory function of activated STAT5 for the gene expression of
CCL1. Importantly, not STAT5 itself, but its target gene cytokine inducible SH2-domain containing protein is required for the
STAT5 inhibitory effect on CCL1 expression. Finally, we show that constitutive activation of STAT5 through a mutated form of
JAK2 (JAK2 V617F) occurring in patients with myeloproliferative disorders similarly suppresses CCL1 expression. Taken to-
gether, we identify novel important inflammatory target genes of OSM which are independent of STAT signaling per se, but
depend on MAPK activation and are partly repressed through STAT5-dependent expression of cytokine inducible SH2-domain
containing protein. The Journal of Immunology, 2008, 181: 7341–7349.
T he appropriate immune response relies on the interactionof various cell types orchestrated by direct cell contact orsoluble factors. As an initial step, recruitment of leuko-
cytes to sites of tissue damage or invaded pathogens occurs. This
process is mainly controlled by members of the chemokine super-
family, in particular by the inducible “inflammatory” chemokines
(1–3). This subfamily comprises the majority of the so far known
50 chemokines in humans and is distinguished from the constitu-
tively expressed “homeostatic” chemokines. Apart from their func-
tion, chemokines can be sorted according to their structure into
four groups, designated C, CX3C, CXC, and CC depending on the
number and spacing of conserved cysteines (1–3). The family
of monocyte-chemoattractant proteins (CCL2/MCP-1, CCL7/
MCP-3, CCL8/MCP-2, and CCL13/MCP-4) has mainly proin-
flammatory activities and exerts its biologic effects through bind-
ing to the G-protein coupled receptors CCR1 and CCR2, which are
present on the cell surface of a variety of cell types (1, 3). CCL1/
I-309 has been originally identified as a gene expressed in acti-
vated T cell lines (4) and specifically binds to CCR8, which is
expressed on the cell surface of polarized Th2 cells and regulatory
T cells as well as macrophages (5–8).
CCL1 as well as the MCP family members CCL7 and CCL8 are
considered to play an important role in the recruitment of mono-
cytes and T lymphocytes to sites of inflammation (9–11). Their
enhanced expression during inflammatory processes is stimulated
by different cytokines in various cell types, i.e., by IL-1, TNF-,
and IFN- in human airway smooth-muscle cells (12), by IL-1 and
IFN- in both fibroblasts and epithelial cells (13) and by endog-
enous IL-1 in monocytes (14).
In this study, we describe the regulation of CCL1, CCL7, and
CCL8 by the IL-6-type cytokine oncostatin M (OSM)3 in primary
human dermal fibroblasts. OSM is a known proinflammatory cy-
tokine, which is secreted by activated monocytes, neutrophils, and
T lymphocytes (15). The human cytokine can signal through two
receptor complexes: the type I receptor complex consisting of
gp130, the common receptor subunit of all IL-6-type cytokines,
and the LIF receptor or the type II receptor complex composed of
gp130 and the OSM receptor  subunit (16). In contrast, murine
OSM only signals through the type II receptor complex (17). Both,
human and murine OSM, are potent activators of the JAK/STAT-
and MAPK-pathways. The canonical JAK/STAT-pathway results
in the phosphorylation of the STAT transcription factors STAT1,
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STAT3, and STAT5, their dimerization and subsequent transloca-
tion into the nucleus where they bind to STAT-specific DNA-
binding elements (18, 19). In many cell types, OSM stimulation
has also been reported to activate the MAPK ERK1/2 and the
stress-activated protein kinases p38 and JNK (20–22). These ki-
nases have been implicated in the regulation of OSM-mediated
chemokine expression in previous studies, i.e., eotaxin expression
in fibroblasts, stromal-derived factor-1 in mesenchymal stem cells
and CCL21 in microvascular endothelial cells (23–25).
To further elucidate the role of OSM within an inflammatory
context, the intracellular mechanisms leading to the release of
CCL1, CCL7, and CCL8 in human dermal fibroblasts (HDFs)
were investigated. OSM-induced transcription of CCL1, CCL7,
and CCL8 was dependent on activation of ERK1 and ERK2 and
their downstream targets c-Jun and c-Fos, forming the transcrip-
tion factor complex AP-1. The chemokine mRNAs were stabilized
by p38 MAPK-dependent inhibition of tristetraprolin and their se-
cretion stimulated the migration of monocytes and T lymphocytes.
Furthermore, we identified a novel negative regulatory mechanism
for the induction of CCL1, which is dependent on STAT5-induced
cytokine inducible SH2-domain containing protein (CIS) expres-
sion. This negative regulatory loop also appears to function in
acute myeloid leukemia cells, which express a constitutively active
form of JAK2.
Materials and Methods
Cell culture and cytokines
Primary HDFs and murine embryonic fibroblasts (MEFs) were maintained
in DMEM (Invitrogen). STAT5a/b heterozygous mice were intercrossed;
single E14.5 embryos were collected and genotyped as described (26).
MEFs were isolated from these embryos and immortalized as described
(27). Primary monocytes, primary T lymphocytes, and HEL cells were
grown in RPMI 1640 medium (Invitrogen). All media were supplemented
with 10% FCS or 1% human serum (PAA) for primary blood cells. Cells
were grown at 37°C in a water-saturated atmosphere containing 5% CO2.
HDFs were generated as described previously (28). Human PBMCs were
isolated from fresh blood or from buffy coats. Monocytes and T cells were
isolated with a Dynal Monocyte Negative Isolation Kit or a Dynal T Cell
Negative Isolation Kit, respectively, as described by the manufacturer (In-
vitrogen). Recombinant human OSM, TNF-, and IL-1 were obtained
from Cell Concepts and murine OSM from R&D Systems. Human LIF was
purchased from Sigma-Aldrich. rIL-6 and soluble IL-6R were prepared as
described (29).
Cell lysis and Western blotting
HDF and MEF cells were stimulated for the indicated times with 20 ng/ml
human or murine OSM. Immediately after stimulation, cells were lysed in
Triton lysis buffer as described previously (30). All steps of cell lysis were
performed at 4°C using ice-cold buffers. Proteins were separated by SDS-
PAGE in 10% gels, followed by electroblotting onto a polyvinylidene di-
fluoride membrane (PALL). Western blot analysis was conducted using the
indicated Abs and the ECL kit (GE Healthcare) according to the manu-
facturer’s instructions. Before reprobing, blots were stripped in 2% SDS
and 100 mM 2-ME in 62.5 mM Tris-HCl (pH 6.7) for 20 min at 70°C. The
pharmacological inhibitors U0126 (Promega), SB202190, SP600125,
AG490, and JAK inhibitor 1 (Merck AG) were applied 30 min prior stim-
ulation with cytokines.
Antibodies
The phosphospecific polyclonal Abs against STAT1(Tyr701),
STAT3(Tyr705), STAT5(Tyr694), ERK1/2(Thr202/Tyr204), MK2(Thr222),
and JAK2 (Tyr1007/1008), as well as STAT1, STAT3, MK2, JAK2, ERK1/2,
c-Fos, c-Jun, and /-tubulin Abs were purchased from Cell Signaling
Technology. The polyclonal Abs against STAT5b (C-17) and p38 (C-20)
were obtained from Santa Cruz Biotechnology and the antiserum against
active-p38 from Promega. The HRP-conjugated secondary Abs were pur-
chased from DakoCytomation.
RT-PCR
Total RNA was isolated from HDFs and MEFs stimulated for the indicated
times with 20 ng/ml human or murine OSM, respectively, using RNeasy
columns (Qiagen) according to the manufacturer’s instructions. RT and
PCR were performed with 1 g of total cell RNA using the OneStep
RT-PCR kit (Qiagen). Detection of specific mRNA for SOCS1, SOCS3,
CIS, CCL1, CCL7, CCL8, and TCA-3 was achieved by using primers
designed to amplify at least one exon (across one intron/exon border to
exclude contamination of cDNA with genomic DNA). GAPDH was used
as an internal standard (31). Amplification was conducted with 35 cycles of
40 s denaturation at 94°C, 30 s annealing at 53–58°C and 30 s extension at
72°C. The amplification was terminated with an extension step for 10 min
at 72°C after the last cycle. PCR products were separated on 1% agarose
gels and stained with ethidium bromide.
RNase protection assays
Total RNA was isolated as described above and protection assays were
carried out using the mCK-5c and hCK8 RiboQuant MultiProbe Template
set from BD Biosciences. Autoradiographies were quantified using a Ty-
phoon 9400 (GE Healthcare).
ELISA
Subconfluent cultures (70–80%) were stimulated for the indicated time
periods and with the indicated cytokines in normal supplemented medium.
Supernatants were collected and analyzed by ELISA. Human CCL1 and
CCL8 as well as murine TCA-3 ELISA kits were purchased from R&D
Systems and used according to the manufacturer’s protocol.
Transfection of murine embryonic fibroblasts
MEFs were transfected using polyethylenimine (PEI). All polyplexes con-
sisting of DNA and PEI were prepared in a sterile isotonic glucose solution
at pH 7.4. The preparation occurred in two steps: 8 g DNA, resuspended
in a total volume of 304 l isotonic glucose solution, were incubated for 10
min at room temperature. Then, 96 l PEI solution (2 mg/ml) were added
and after thorough mixing incubated for 20 min at room temperature. The
transfection mixture was added to 1 105 MEFs in 2.6 ml OptiMEM/10%
FCS (Invitrogen). After 4 h at 37°C the transfection medium was removed
and replaced by DMEM/10% FCS. Forty-four hours later cells were stim-
ulated and lysed as described above.
Modified Boyden chamber assay
Primary monocytes and T-lymphocytes were incubated for 2 h after iso-
lation in RPMI 1640 containing 1% human serum and maintained in
DMEM without serum throughout the assay. Transwell inserts (6.5 mm
diameter, 8 m pore size; Corning Costar) were coated with human fi-
bronectin. Into each transwell, 1  105 monocytes or T-lymphocytes/100
l were transferred. The transwell was inserted into a 24-well plate con-
taining 800 l supernatant of OSM-stimulated HDFs or IL-1-stimulated
HEL cells and monocytes, respectively. Cell migration to the bottom cham-
ber was assessed 4 h later. To block migration, specific Abs (R&D Sys-
tems) were added to the supernatant in the bottom chamber. Every migra-
tion assay was performed at least three times in triplicate.
Small interfering RNA (siRNA) transfection
HDFs were seeded in 6-well plates and allowed to grow to 70% confluency
for 24 h. Transient transfections were performed with DharmaFECT1
transfection reagent (Perbio Europe) according to the manufacturer’s pro-
tocol. In brief, 75 nM siRNA (OnTargetPlus SMARTpools; Perbio Europe)
or nonsilencing off-target siRNA (Qiagen) and DharmaFECT1 transfection
reagent were each diluted first in reduced serum medium (OptiMEM; In-
vitrogen) and then mixed. The mixtures were allowed to incubate for 30
min at room temperature and then added in drops to each culture dish
containing medium without FCS. Two hours later, complete DMEM me-
dium was added. Forty-eight hours after transfection the cells could be
stimulated and further investigated.
Statistical analysis
All data are expressed as mean SD for at least three separate experiments
(Student’s t test). A probability p  0.05 was considered significantly
different. All analyses were performed using the statistical software Graph-
Pad Prism (GraphPad Prism for Windows, Version 3.00, GraphPad
Software).
Results
Oncostatin M stimulates production of CCL1, CCL7, and CCL8
by primary human dermal fibroblasts
To elucidate the effect of OSM on the expression of CCL1, CCL7,
and CCL8 in HDFs, their mRNA levels were determined by RNase
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protection assays. Human OSM (20 ng/ml) stimulated the tran-
scription of CCL1, CCL7, and CCL8 transcription time depen-
dently with a peak at 60 min. Significant quantities of all mRNAs
were still detectable 4 h after stimulation (Fig. 1, A and B).
ELISAs, conducted for CCL1 and CCL8 to quantify protein levels
in HDF supernatants, confirmed the secretion of up to 300 pg/ml
CCL1 and up to 600 pg/ml CCL8 (Fig. 1C). Once produced, the
proteins were stable for at least 12 h in cell supernatants. Further-
more, analysis of the required OSM dose demonstrated that en-
hanced transcription of the chemokines starts at 1 ng/ml and
reached a plateau at 10 ng/ml (Supplementary Figure S1A).4 To
evaluate the ability of other inflammatory cytokines to induce
CCL1, CCL7, and CCL8, HDFs were stimulated for 4 h with 100
ng/ml LIF, 20 ng/ml IL-6 (in combination with 0.5 g/ml soluble
IL-6R), 10 ng/ml TNF-, or 10 ng/ml IL-1. TNF- and IL-1
up-regulated CCL1, CCL7, and CCL8 mRNA levels to a similar
extent as OSM (Supplementary Figure S1, B–D). However, for
IL-1- and TNF--treated HDFs, a remarkable delay in protein
secretion was detectable; only OSM induced maximal chemokine
secretion already 1 h after cytokine stimulation. After 24-h stim-
ulation though, all three cytokines stimulated substantial release of
chemokines (Fig. 1D). In contrast to the proinflammatory cyto-
kines, IL-6 stimulation induced only marginal increases in CCL7
and CCL8 mRNA levels and LIF completely failed to initiate
mRNA expression of the analyzed chemokines (Supplementary
Figure S1, B). In summary, OSM is a potent inducer of CCL1,
CCL7, and CCL8 expression comparable to IL-1 and TNF-,
however, maximal chemokine secretion is achieved at earlier time
points.
4 The online version of this article contains supplementary material.
FIGURE 1. OSM-induced expres-
sion of CCL1, CCL7, and CCL8. A,
The mRNA levels of CCL1, CCL7,
and CCL8 in HDFs treated with 20
ng/ml OSM are determined by RNase
protection assays and one representa-
tive of three independent experiments
is shown. B, RNase protection assay
results were quantified by phospho-
imager, the relative mRNA levels
were normalized to those of GAPDH
and expressed as fold induction rela-
tive to unstimulated cells. The values
shown are mean SD (n 3). , p
0.05 vs control. C, Protein amounts of
CCL1 and CCL8 in culture superna-
tants of OSM-treated HDFs (20 ng/
ml) were determined by ELISA. Data
are expressed as mean  SD (n  4).
, p  0.05 vs control. D, Protein
amounts of CCL1 and CCL8 in cul-
ture supernatants of OSM- (20 ng/
ml), IL-1- (10 ng/ml) or TNF-- (10
ng/ml) treated HDFs (1 and 24 h)
were determined by ELISA. Data are
expressed as mean  SD (n  3).
, p  0.05 vs control.
FIGURE 2. OSM-induced CCL1 and CCL8 expression mediates migra-
tion of primary monocytes and T lymphocytes. A and B, Culture superna-
tants of OSM-treated HDFs (20 ng/ml, 3 h) were used to analyze the po-
tential of secreted chemokines to induce migration in a modified Boyden
chamber assay as described in Materials and Methods. The numbers of
migrated monocytes or T lymphocytes were determined and compared
with controls (untreated DMEM). Values shown are mean  SD (n  3).
, p  0.05 vs control; d, p  0.05 vs Ab control.
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OSM-induced CCL1 and CCL8 expression leads to migration
of monocytes and T lymphocytes
As both CCL1 and CCL8 have been implicated in the recruitment
of monocytes and T lymphocytes, we wondered whether the
amounts of CCL1 and CCL8 induced by OSM are sufficient to
stimulate leukocyte migration. HDFs were stimulated with 20
ng/ml OSM for 3 h and the chemokine-containing supernatant was
added to a modified Boyden chamber assay. Direct OSM treatment
or supernatant from untreated HDFs had no influence on the mi-
gration of the leukocytes (Fig. 2, A and B, second and third col-
umn). In contrast, the supernatant of OSM-stimulated HDFs in-
duced the migration of 50% of the seeded monocytes or T
lymphocytes to the bottom reservoir of the transwell ( fourth col-
umn). To evaluate the contribution of CCL1 and CCL8 to migra-
tion, we added neutralizing Abs to both chemokines, alone or in
combination. As expected, neutralization of CCL1 reduced the mi-
gration of monocytes (Fig. 2A, sixth column) and T lymphocytes
(Fig. 2B, sixth column) while the blockade of CCL8 significantly
reduced migration of monocytes (Fig. 2A, seventh column), but
only had a minor inhibitory effect on T lymphocytes (Fig. 2B,
seventh column). Simultaneous addition of both Abs revealed no
additive effect (Fig. 2, A and B, eighth column).
In conclusion, OSM induced the migration of leukocytes via
HDF-released factors mediated in part by CCL1 and CCL8.
OSM-induced ERK1/2 activation is involved in transcription of
CCL1, CCL7, and CCL8 while p38 MAPK stabilizes the mRNA
through a tristetraprolin (TTP)-inhibiting mechanism
Next, we investigated which signal transduction pathways partic-
ipate in CCL1, CCL7, and CCL8 transcription. Established phar-
macological inhibitors of the three MAPK families ERK, p38, and
JNK served as tools to assess their roles in OSM-mediated CCL1
and CCL8 induction. Preincubation of HDFs with the p38 MAPK
inhibitor SB202190 or the ERK1/2 inhibitor U0126, but not the
JNK inhibitor SP600125, led to a significant reduction in the pro-
tein levels of CCL1 and CCL8 detected in HDF supernatants 3 h
after OSM stimulation (Fig. 3A). Analysis of mRNA levels by
RNase protection assays proved to be consistent with the results of
protein assays (data not shown). Effectiveness of all inhibitors was
FIGURE 3. OSM-induced CCL1 and CCL8 expression is dependent on MAPK signaling. A, HDFs were pretreated with 10 M SB202190, 10 M
U0126, or 10 M SP600125 for 30 min, exposed to 20 ng/ml OSM for 3 h and secreted protein amounts of CCL1 or CCL8 were measured by ELISA from
culture supernatants. Data are expressed as mean  SD (n  5). , p  0.05 vs control. B, HDFs were stimulated with 20 ng/ml OSM for 30 min.
Subsequently, cells were washed and cultivated for additional 20 min in OSM-free medium containing actinomycin D (4 M) to block transcription.
Afterward, 10 M SB202190 or 10 M U0126 were added to the medium before the cells were finally stimulated a second time with OSM for the indicated
time periods. CCL1 mRNA and GAPDH mRNA levels were analyzed by RT-PCR. One representative of three independent experiments is shown. C, HDFs
were transfected with TTP siRNA as described in Materials and Methods. Forty-eight hours after transfection, cells were pretreated with 10 M SB202190
for 20 min and subsequently stimulated with 20 ng/ml OSM for 3 h. The amounts of CCL1 or CCL8 in culture supernatants were measured by ELISA.
Data are expressed as mean SD (n 3). , p 0.05 vs control. D, HDFs were transfected with control, c-Jun, or c-Fos siRNA, respectively. The amounts
of CCL1 or CCL8 in culture supernatants were measured by ELISA. Data are expressed as mean  SD (n  4). , p  0.05 vs control. To analyze
knock-down efficiency whole cellular lysates were subjected to Western blot analysis using specific Abs against c-Fos and c-Jun. Tubulin expression served
as loading control.
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demonstrated by Western blot analysis of target proteins (Supple-
mentary Figure S2A).
To corroborate whether p38 and ERK1/2 were directly involved
in initiation of transcription or stabilization of mRNA, we com-
pared the time-dependent loss of CCL1, CCL7, and CCL8 mRNA
in the presence or absence of OSM and the respective pharmaco-
logical inhibitors SB202190 or UO126 (Fig. 3B and Supplemen-
tary Fig. S2B). Chemokine expression in HDFs was induced by
stimulation with OSM for 30 min. Afterward, OSM was removed
and actinomycin D was added to the medium to prevent ongoing
mRNA synthesis. After 20-min incubation with actinomycin D,
OSM was added to restart activation of signal transduction in the
absence or presence of the MAPK inhibitors SB202190 or UO126.
Whereas CCL1 mRNA induced by 30 min OSM treatment was
degraded only after 60 min of additional OSM treatment, the pres-
ence of the p38 inhibitor SB202190 in the supernatant prevented
stabilization of the mRNA levels and led to rapid degradation al-
ready after additional 15 min incubation (Fig. 3B, left panel). The
MEK1/2 inhibitor UO126, however, had no destabilizing effect on
CCL1 mRNA (Fig. 3B, right panel). Equivalent results were ob-
tained for CCL7 and CCL8 mRNA (Supplementary Fig. S2B).
Control experiments demonstrated that OSM was not able to in-
duce chemokine transcription in the presence of actinomycin D
(Supplementary Fig. S2B, right).
Stabilization of AU-rich mRNAs can be mediated by p38
MAPK-dependent phosphorylation and subsequent degradation of
the mRNA destabilizing protein TTP. Therefore, one could envis-
age a similar mechanism for OSM-activated p38 MAPK. Conse-
quently, chemokine mRNA should be stabilized in TTP knock-
down cells irrespective of treatment with the p38 inhibitor
SB202190. Indeed, mRNA levels of CCL1, CCL7, and CCL8
showed a prolonged half-life in TTP siRNA-treated HDFs despite
inhibition of p38 by SB202190 (Supplementary Fig. S2C). Con-
sistently, the strong reduction of OSM-induced CCL1 and CCL8
secretion in the presence of SB202190 was abrogated in cells pre-
treated with TTP siRNA (Fig. 3C, compare sixth column with
ninth column).
Because inhibition of ERK activation had no influence on che-
mokine stability, we investigated a direct involvement in transcrip-
tion by depleting the mRNAs of two prominent ERK1/2 immedi-
ate early target genes, c-Jun and c-Fos (Fig. 3D, right panel).
Indeed, lack of c-Jun or c-Fos strongly reduced the capacity of
OSM to induce transcription and secretion of CCL1 (Fig. 3D, left
panel) and CCL8 (Fig. 3D, middle panel).
OSM-induced production of CCL1, but not CCL8, is negatively
regulated by STAT5
To investigate whether the OSM-stimulated CCL1 and CCL8 ex-
pression requires the JAK/STAT signaling cascade as well, HDFs
were transfected with specific siRNAs against STAT1, STAT3,
and STAT5, respectively. Although the analysis of whole cellular
extracts indicated a complete knock-down of activated STAT fac-
tors (Fig. 4A), neither STAT1 nor STAT3 absence affected CCL1
or CCL8 production (Fig. 4B). Knock-down of STAT5, however,
resulted in a strong increase of CCL1 protein secretion (Fig. 4B,
upper panel).
FIGURE 4. CCL1 and TCA-3 ex-
pression are negatively regulated by
STAT5 activation. A, Western blot
detection of whole cellular extracts of
siRNA transfected HDFs, treated
with OSM (20 ng/ml, 3 h), using
specific antisera against phospho-
STAT1, -STAT3, or -STAT5. Subse-
quently the blots were stripped and
reprobed with antisera recognizing
proteins irrespectively of their activa-
tion. B, Amounts of CCL1 or CCL8
in culture supernatants of transfected
HDFs were measured by ELISA.
Data are expressed as mean  SD
(n  5). , p  0.05 vs control. C,
MEF cells were treated with 20 ng/ml
murine OSM for the indicated time
periods. The mRNA levels of TCA-3
were determined by RNase protection
assays and a representative experi-
ment of three independent experi-
ments is shown. RNase protection as-
say results were quantified and the
relative levels of TCA-3 following
OSM stimulation were normalized to
those of GAPDH and compared with
unstimulated cells. The values shown
are mean  SD (n  3). , p  0.05
vs control. D, ELISA to detect protein
amounts of TCA-3 in MEF cells
treated with murine OSM (20 ng/ml)
for the indicated time periods.
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Previous studies have shown that STAT5 can be directly acti-
vated by JAK2 after cytokine stimulation (30, 32). To corroborate
our results, we treated HDFs with AG490, an inhibitor with higher
affinity to JAK2 than to other JAK family members. In fact, sig-
nificantly increased CCL1 production is also observed after the
administration of AG490 (Supplementary Fig. S3, left panel).
However, the inhibitor does not exert any effect on the OSM-
induced CCL8 expression (right panel).
TCA-3 represents the murine homologue to human CCL1.
We therefore assessed the TCA-3 mRNA and protein levels in
wild-type and STAT5/ MEF cells after OSM stimulation. A
clear though transient induction of TCA-3 mRNA was observed
in wild-type cells (Fig. 4C, left), whereas significantly elevated
TCA-3 mRNA levels were detectable in STAT5-deficient MEFs
up to 24 h after OSM stimulation (Fig. 4C, right). These elevated
levels of TCA-3 mRNA in STAT5-deficient MEFs resulted in
clearly elevated protein levels of TCA-3 in the supernatants after
24 h of stimulation (Fig. 4D).
To further investigate which factor(s) might be responsible for
the negative regulation of TCA-3 in wild-type MEFs, STAT5 it-
self, a STAT5-inducible gene or secondary players, the activation
patterns of prominent members of the OSM-inducible pathways
were analyzed (Fig. 5A). We observed very similar phosphoryla-
tion kinetics for STAT1, STAT3, ERK1/2, and p38 in wild-type
compared to STAT5/ MEFs after stimulation with OSM over
the indicated periods of time. As expected, the STAT5 activation
was not detectable in STAT5/ cells (third panel, left). The anal-
ysis of common feedback inhibitors of IL-6-type cytokine signal-
ing, SOCS1 and SOCS3, shows that both proteins are inducible by
OSM in wild-type and STAT5-deficient cells. Induction of the
STAT5-dependent feedback inhibitor CIS, however, is not ob-
served in STAT5/ MEFs (Fig. 5B, third panel). Based on these
results, we studied the role of CIS on OSM-induced CCL1 expres-
sion. We transfected HDFs with CIS siRNA and subsequently
stimulated with OSM (Supplementary Fig. S4A). The secreted
amount of CCL1 was significantly increased in CIS siRNA-trans-
fected cells 3 h post OSM stimulation (Fig. 5C, upper panel),
whereas the OSM-induced CCL8 expression is not affected by the
knock-down of CIS (Fig. 5C, lower panel). We conclude that the
elevated levels of CCL1 in the absence of STAT5a/b are due to
the failure of OSM to induce CIS expression. Consequently, over-
expression of CIS reduced the elevated mRNA and protein expres-
sion of TCA-3 in STAT5-deficient MEFs to levels produced by
wild-type MEFs (Fig. 5D, Supplementary Fig. S4, B and C). Nei-
ther STAT5 nor CIS knock-down affected the IL-1 or TNF--
mediated expression of CCL1 (Supplementary Fig. S4D).
Constitutive activation of the JAK2/STAT5 pathway in acute
myeloid leukemia cells suppresses CCL1 expression
The STAT transcription factors, particularly STAT3 and STAT5,
are known to be constitutively activated in a number of tumor
cells. Recently, a mutation in human JAK2 (JAK2 V617F) has
been identified in patients with myeloproliferative disorders (33).
This mutation in the pseudokinase domain of JAK2 results in the
constitutive activation of the enzyme and consequently in the ac-
tivation of STAT5 and ERK1/2 (Fig. 6A, lane 1). Because we
identified a negative regulatory function of STAT5/CIS in sup-
pressing the expression of CCL1, we predicted that this chemokine
production is also constitutively suppressed in acute myeloid leu-
kemia cells harboring the JAK2 V617F mutation (HEL cells). In-
deed, these cells constitutively express CIS (Fig. 6B, lane 1) and,
in contrast to primary monocytes from healthy donors, stimulation
FIGURE 5. The STAT5-depen-
dent negative regulation of CCL1 ex-
pression is mediated by CIS. A, West-
ern blot detection of whole cellular
extracts of MEFs, treated with OSM
(20 ng/ml for the indicated time peri-
ods), using Abs specific for phosphor-
ylated STAT1, STAT3, STAT5,
ERK1/2, and p38. The blots were
stripped and reprobed with antisera
recognizing the proteins irrespec-
tively of their activation. B, RT-PCR
to detect SOCS1, SOCS3, and CIS
mRNA levels in MEFs stimulated
with 20 ng/ml murine OSM for 1 h.
One representative of three indepen-
dent experiments is shown. C, HDFs
were transfected with CIS siRNA and
then stimulated with 20 ng/ml human
OSM for 3 h. The protein amounts of
CCL1 or CCL8 in culture superna-
tants were measured by ELISA. Data
are expressed as mean  SD (n  4).
, p  0.05 vs control. D, MEF cells
were transiently transfected with ex-
pression vectors for muCIS or control
vector and stimulated with mOSM as
indicated. The protein amounts of
TCA-3 in culture supernatants were
measured by ELISA. Data are ex-
pressed as mean SD (n 3). , p
0.05 vs MOCK-transfected control.
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with IL-1 or OSM could not induce secretion of CCL1 in HEL
cells (Fig. 6C, fourth column; Fig. 6E, second and third column).
To abrogate the constitutive activation of JAK2, HEL cells were
incubated for 12 h with the JAK inhibitor-1, a general inhibitor of
all Janus kinases. This treatment abrogated the constitutive acti-
vation of JAK2, STAT5, and ERK1/2 (Fig. 6A, lane 3). Further-
more, constitutive expression of CIS was inhibited (Fig. 6B, lane
2). Because OSM itself, however, relies on the activation of JAK1
and JAK2 to initiate its own signaling cascade, treatment of HEL
cells with JI-1 precludes stimulation with OSM. Thus, OSM which
is usually a strong inducer of CIS (Fig. 5B) could no longer stim-
ulate CIS expression (Fig. 6B, lane 4) or CCL1 expression (Fig.
6D, third column). IL-1, however, signals via IRAK and IKK and
therefore independent of Janus kinases. Hence, this cytokine is still
actively working in the presence of JI-1 and was additionally used
for the experiments. Interestingly, in the absence of the constitu-
tive active JAK2/STAT5/CIS pathway, IL-1 stimulation of HEL
cells strongly induced CCL1 expression (Fig. 6D, second column).
To directly prove the involvement of CIS in the suppression of
CCL1 expression in HEL cells we abrogated the constitutive CIS
expression through siRNA knock-down (Fig. 6E, lower panel).
Exclusive knock-down of CIS resulted in constitutive secretion of
CCL1 (Fig. 6E, upper panel, seventh column). Because we could
show that c-Jun and c-Fos are important positive regulators of
CCL1 expression (Fig. 3D, left panel), the constitutive activation
of the ERK1/2 pathway in HEL cells explains the constitutive
expression of CCL1. This constitutive expression could be slightly
increased by additional stimulation with OSM (Fig. 6E, ninth col-
umn), but not by IL-1 (eighth column). Because IL-1 itself does
not induce CIS expression knock-down of CIS in JAK inhibitor-1
treated HEL cells had no further stimulatory effect on IL-1-in-
duced CCL1 (Supplementary Fig. S5, eighth column). However, it
is important to note that the constitutively expressed CIS (due to
the JAK2 V617F mutation) can inhibit IL-1-induced CCL1 ex-
pression in trans in HEL cells.
Discussion
The results presented in this study demonstrate for the first time
that human OSM is able to induce CCL1, CCL7, and CCL8 ex-
pression, both at mRNA and protein levels in HDFs to levels com-
parable to those found for the hitherto strongest stimulators IL-1
and TNF-. Compared with these well-known proinflammatory
cytokines OSM acts significantly faster on HDFs leading to max-
imal secretion of the chemokines already after 1 h of stimulation.
The migration assays performed for monocytes and T lymphocytes
underline the physiological relevance and efficacy of the OSM-
mediated CCL1 and CCL8 induction. Former publications dem-
onstrated that OSM-induced eotaxin secretion is important in the
eosinophilic inflammatory process (23) and an increased produc-
tion of CCL21 in lymphatic endothelial cells promoted migration
of dendritic cells into lymph nodes (25).
Interestingly, the close relative of OSM, LIF, cannot induce
CCL1 and/or CCL8, indicating that OSM-induced chemokine ex-
pression of CCL1, CCL7, and CCL8 is likely to be mediated via
the OSMR/gp130 receptor complex (type II) and not by the LIFR/
gp130 receptor complex (type I), also used by LIF.
FIGURE 6. The JAK2 V617F mutation leads to CCL1 suppression. A, HELs were left untreated or incubated with 1 M JAK inhibitor-1 (JI-1) or the
solvent DMSO for 12 h. Lysates were prepared and subjected to Western blot analysis using Abs specific for phosphorylated JAK2, STAT5, and Erk1/2.
The blots were stripped and reprobed with antisera recognizing the proteins irrespectively of their activation. B, HELs were preincubated with 1 M JAK
inhibitor-1 (JI-1) for 12 h and then stimulated with 10 ng/ml IL-1 or 20 ng/ml OSM for 1 h. RNA was isolated and RT-PCR used to detect CIS mRNA.
C, Primary monocytes and HEL cells were stimulated with 10 ng/ml IL-1 for 3 h. The protein amounts of CCL1 in culture supernatants were measured
by ELISA. Data are expressed as mean  SD (n  4). , p  0.05 vs control. D, HELs were preincubated with 1 M JI-1 for 12 h and then stimulated
10 ng/ml IL-1 or 20 ng/ml OSM for 3 h. The protein amounts of CCL1 in culture supernatants were measured by ELISA. Data are expressed as mean 
SD (n  3). , p  0.05 vs control. E, HELs were transfected with control or CIS siRNA and stimulated with 10 ng/ml IL-1 or 20 ng/ml OSM for 3 h.
The protein amounts of CCL1 in culture supernatants were measured by ELISA. Data are expressed as mean  SD (n  3). , p  0.05 vs control. To
analyze knock-down efficiency RT-PCR was used to detect CIS mRNA levels.
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Previous reports indicated that OSM uses the JAK/STAT- or the
MAPK-pathway to induce the chemokines CCL2, eotaxin, or stro-
mal-derived factor-1 (23, 25, 34, 35). In this study, we show for the
first time the involvement of OSM-induced signaling pathways in
CCL1, CCL7, and CCL8 transcription by the use of siRNA inter-
ference as well as well established pharmacological inhibitors
(SB202190, U0126, and SP600125). These studies demonstrated
that JNK is dispensable for the expression of CCL1 or CCL8,
whereas p38 and ERK1/2 are crucial for the expression of these
chemokines. Closer investigation of the underlying molecular
mechanism demonstrated that p38 MAPK is involved in mRNA
stabilization of CCL1, CCL7, and CCL8 through a TTP-destabi-
lizing activity. TTP is a well-known mRNA-destabilizing protein
mediating mRNA degradation of many proinflammatory mediators
through binding to AU-rich elements (36, 37).
ERK1/2, however, appeared to be involved directly in the en-
hanced transcription through AP-1 transcription factors because
depletion of c-Jun or c-Fos strongly reduced expression of CCL1
and CCL8. A similar result has recently been described for CCL2
(35). Of note, the activation of ERK1/2 alone appears not to be
sufficient for stable mRNA levels of these chemokines, because
IL-6 is also a potent activator of this MAPK in dermal fibroblasts
as shown previously (21), however, does not stimulate substantial
transcription of the chemokines. None of the siRNAs used to
down-regulate STAT1, STAT3, or STAT5 affected the expression
of CCL8. This finding suggests a STAT-independent transcription
of CCL8 in response to OSM and further supports the observed
importance of the MAPK.
STAT1 and STAT3 have no influence on the expression of
CCL1, whereas OSM-activated STAT5 appears to have a repres-
sive effect on the secretion of CCL1 as demonstrated by: 1) in-
creased expression after transfection of HDFs with siRNA against
STAT5, 2) prolonged transcription and enhanced secretion of the
CCL-1 homologue in murine STAT5-deficient MEFs (TCA-3),
and 3) pretreatment of HDFs with the JAK2 inhibitor AG490 be-
fore OSM-stimulation which significantly enhanced the expression
of CCL1. Previous work has highlighted the importance of JAK2
for the STAT5 tyrosine phosphorylation (30, 32).
Interestingly, activated STAT3 has been attributed to a compa-
rable role in tumor cells, where it represses the expression of in-
flammatory cytokines and chemokines and therefore constrains the
immune system in fighting the tumor (38). Because activated
STAT5 is found in a large variety of tumors, particularly various
leukemias, it is tempting to speculate that activated STAT5 could
act in a similar fashion. Indeed, we demonstrate that IL-1 can
stimulate expression of CCL1 in a human acute myeloid leukemia
cell line that expresses a constitutively active variant of JAK2
(V617F) only if the JAK/STAT-pathway is inhibited by the JAK
inhibitor-1.
The enhanced expression of CCL1 in the absence of STAT5 is
not due to aberrant phosphorylation of STAT3 or STAT1 by OSM
as described for STAT5a/b liver specific mutant mice in response
to growth hormone (39). Also no perturbances of p38 and ERK1/2
expression and activity relevant for the induction of CCL1 and
CCL8 have been observed in STAT5/ MEFs. However, the
comparison of the feedback inhibitors SOCS1, SOCS3, and CIS
within the OSM-induced pathway showed a lack of induction of
CIS in STAT5/ MEF cells, a classical STAT5 target gene and
a feedback inhibitor of STAT5 (40, 41). We could functionally
prove that the missing expression of CIS is responsible for the
elevated CCL1 expression, because deficiency of CIS led to an
increase of CCL1 secretion and overexpression of CIS reduced
elevated CCL1 amounts in STAT5-deficient cells back to wild-
type levels. Similarly, knock-down of the constitutive CIS expres-
sion in the acute myeloid leukemia cell line resulted in constitutive
CCL1 secretion. In the classical feedback process, CIS binds to
phosphorylated tyrosine residues within the cytoplasmic domain of
STAT5-activating receptors and blocks further activation of
STAT5 (41). In line with this, CIS-transgenic mice are virtually
identical to STAT5a/b knock-out mice (42). This classical feed-
back mechanism, however, cannot serve as explanation for the
observed negative effect of STAT5 because we would have ex-
pected to see a decrease of CCL1 expression upon knock-down of
CIS. Therefore, another molecular mechanism has to be involved.
CIS has also been described to act as a scavenger protein guiding
phosphorylated proteins, e.g., receptors, to degradation via the
ubiquitin/proteasome-dependent pathway (43, 44).
Our findings that all investigated pathways besides STAT5, i.e.,
STAT1, STAT3, ERK1/2, and p38, are unaffected in STAT5-de-
ficient MEFs treated up to 16 h with OSM argues against an in-
volvement of CIS in degradation of gp130, the oncostatin M re-
ceptor or membrane-proximal signaling events. Remarkably, CIS
does not only suppress CCL1 activation in response to cytokines
which normally induce expression of CIS like OSM, i.e., it does
not only act in cis-, but also inhibits CCL1 expression mediated
through cytokines like IL-1 which themselves do not induce CIS
expression, i.e., it acts also in trans. This result argues for a CCL1-
promoter proximal activity of CIS. Additional experiments are
therefore required to elucidate the molecular mechanism(s) how
CIS is involved in the regulation of CCL1 expression.
Taken together, we identified novel important inflammatory tar-
get genes of OSM which are independent of STAT signaling per
se, but depend on MAPK activation and are partly repressed
through cytokine-induced or constitutive expression of CIS.
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